Abstract
Regenerative Medicine (RM) has the promise to revolutionize the treatment of many debilitating diseases for which the current therapies are inadequate. To realize the full potential of RM, a pragmatic approach needs to be taken by all stakeholders keeping in mind the lessons learnt from recombinant protein manufacturing, gene therapy trials, etc., to develop novel service delivery models for economic viability and regulatory processes in the absence of long-term data. In this chapter, we focus on the three main drivers of RM field and discuss the potential pitfalls and possible ways to mitigate them in order to move the field closer to clinical implementation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amos PJ, Cagavi Bozkulak E, Qyang Y (2012) Methods of cell purification: a critical juncture for laboratory research and translational science. Cells Tissues Organs 195(1–2):26–40
Baumann K (2012) Stem cells: an ageing decline. Nat Rev Mol Cell Biol 13(11):681
Becker AJ, Mc CE, Till JE (1963) Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197:452–454
Benninghoff J (2009) Stem cell approaches in psychiatry–challenges and opportunities. Dialogues Clin Neurosci 11(4):397–404
Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE et al (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329(5997):1345–1348
Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817–4828
Carmen J, Burger SR, McCaman M, Rowley JA (2012) Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen Med 7(1):85–100
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954):818–823
Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F et al (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467(7313):318–322
Chen Y, Peng C, Sullivan C, Li D, Li S (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem 10(2):111–115
Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA et al (2010) Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 12(6):743–749
Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C (2012) A decade of cell therapy clinical trials (2000–2010). Regen Med 7(4):455–462
Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51(6):987–1000
Davis ME, Hsieh PC, Grodzinsky AJ, Lee RT (2005) Custom design of the cardiac microenvironment with biomaterials. Circ Res 97(1):8–15
Dengler J, Song H, Thavandiran N, Masse S, Wood GA, Nanthakumar K et al (2011) Engineered heart tissue enables study of residual undifferentiated embryonic stem cell activity in a cardiac environment. Biotechnol Bioeng 108(3):704–719
Ebert AD, Liang P, Wu JC (2012) Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol 60(4):408–416
Eisenstein M (2012) Stem cells: don’t believe the hype. Nature 484(7393):S5
Fenske DB, Chonn A, Cullis PR (2008) Liposomal nanomedicines: an emerging field. Toxicol Pathol 36(1):21–29
Hosseinkhani H, Tabata Y (2006) Self assembly of DNA nanoparticles with polycations for the delivery of genetic materials into cells. J Nanosci Nanotechnol 6(8):2320–2328
Huang P, He Z, Ji S, Sun H, Xiang D, Liu C et al (2011) Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475(7356):386–389
Hutter G, Zaia JA (2011) Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 163(3):284–295
Jensen J, Hyllner J, Bjorquist P (2009) Human embryonic stem cell technologies and drug discovery. J Cell Physiol 219(3):513–519
Laschke MW, Harder Y, Amon M, Martin I, Farhadi J, Ring A et al (2006) Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Eng 12(8):2093–2104
Lovett M, Lee K, Edwards A, Kaplan DL (2009) Vascularization strategies for tissue engineering. Tissue Eng Part B Rev 15(3):353–370
Luijten PR, van Dongen GA, Moonen CT, Storm G, Crommelin DJ (2012) Public-private partnerships in translational medicine: concepts and practical examples. J Control Release 161(2):416–421
Mendelson K, Schoen FJ (2006) Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 34(12):1799–1819
Miller FD, Kaplan DR (2012) Mobilizing endogenous stem cells for repair and regeneration: are we there yet? Cell Stem Cell 10(6):650–652
Miller JS, Stevens KR, Yang MT, Baker BM, Nguyen DH, Cohen DM et al (2012) Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater 11(9):768–774
Muller-Sieburg CE, Sieburg HB, Bernitz JM, Cattarossi G (2012) Stem cell heterogeneity: implications for aging and regenerative medicine. Blood 119(17):3900–3907
Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ (2009) Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460(7252):259–263
Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ et al (2011) Induction of human neuronal cells by defined transcription factors. Nature 476(7359):220–223
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733
Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255(5052):1707–1710
Robinton DA, Daley GQ (2012) The promise of induced pluripotent stem cells in research and therapy. Nature 481(7381):295–305
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550–4557
Rosso F, Marino G, Giordano A, Barbarisi M, Parmeggiani D, Barbarisi A (2005) Smart materials as scaffolds for tissue engineering. J Cell Physiol 203(3):465–470
Sanchez-Ramos J, Cimino C, Avila R, Rowe A, Chen R, Whelan G et al (2012) Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease. J Alzheimers Dis 31(4):843–855
Sartipy P, Bjorquist P (2011) Concise review: human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment. Stem Cells 29(5):744–748
Seale P, Rudnicki MA (2000) A new look at the origin, function, and “stem-cell” status of muscle satellite cells. Dev Biol 218(2):115–124
Silva EA, Mooney DJ (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5(3):590–598
Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z et al (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20(5):674–688
Soen Y, Mori A, Palmer TD, Brown PO (2006) Exploring the regulation of human neural precursor cell differentiation using arrays of signaling microenvironments. Mol Syst Biol 2:37
Stoop R (2008) Smart biomaterials for tissue engineering of cartilage. Injury. 39(1):S77–S87
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147
Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284):1035–1041
Wagers AJ (2012) The stem cell niche in regenerative medicine. Cell Stem Cell 10(4):362–369
Williams D (2005) Environmentally smart polymers. Med Device Technol 16(4):9–10
Wilson JM (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96(4):151–157
Zheng Y, Chen J, Craven M, Choi NW, Totorica S, Diaz-Santana A et al (2012) In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A 109(24):9342–9347
Zweigerdt R (2009) Large scale production of stem cells and their derivatives. Adv Biochem Eng Biotechnol 114:201–235
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Viswanathan, S., Joshi, C. (2012). Regenerative Medicine: Challenges and Perspectives for Successful Therapies. In: Heber-Katz, E., Stocum, D. (eds) New Perspectives in Regeneration. Current Topics in Microbiology and Immunology, vol 367. Springer, Berlin, Heidelberg. https://doi.org/10.1007/82_2012_290
Download citation
DOI: https://doi.org/10.1007/82_2012_290
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35809-8
Online ISBN: 978-3-642-35810-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)